Crispr stock, alongside other gene-editing equities, pulled a bullish move Thursday — bounding for a breakout from a cup-with ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the double ...

Researchers building disease models need precision: models that faithfully reproduce patient-relevant genetic variants, not ...

With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for ...

Affecting an estimated 100,000 people globally, cystic fibrosis (CF) cases stem from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. In the past several decades, ...

The global in vivo gene editing market was valued at USD 3.4 billion in 2025 and is forecast to reach USD 22.6 billion by 2036, growing at a 16.8% CAGR from 2026. Growth is driven by CRISPR, base and ...

CRISPR may be a powerful technology for gene editing, but the system existed in bacteria long before scientists began using it. For billions of years, CRISPR has acted as a natural immune system in ...

CRISPR-Cas systems protect bacteria against viruses and other mobile genetic elements. Here, Brodmann et al. identify two proteins that interact with RNA polymerase to control expression of a ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Beam Therapeutics said Monday that it used ...

Scientists at St. Jude Children’s Research Hospital report that they have developed an unbiased, sensitive, and resource-efficient method to identify small, off-target sites that pose a safety risk ...

A study by researchers at Columbia University Vagelos College of Physicians and Surgeons has found that new cutting-edge ...